LifeMD, Inc. 8.875% Series A Cumulative Perpetual Preferred Stock financials
$23.15−0.22%
Close Sep 25, 2026 · split-adjustedRevenue
Net income
Income statement & cash flow
| Fiscal year | FY25 Dec 31 | FY24 Dec 31 | FY23 Dec 31 | FY22 Dec 31 | FY21 Dec 31 |
|---|---|---|---|---|---|
| Revenue | $194.1M | $154.8M | $152.5M | $119.0M | $92.9M |
| Gross profit | $166.3M | $133.4M | $133.6M | $100.4M | $74.9M |
| Gross margin | 85.7% | 86.2% | 87.6% | 84.3% | 80.6% |
| Operating income | -$7.7M | -$20.4M | -$14.5M | -$43.4M | -$54.3M |
| Net income | $11.2M | -$24.5M | -$23.7M | -$48.6M | -$61.8M |
| Net margin | 5.8% | −15.8% | −15.5% | −40.9% | −66.5% |
| Diluted EPS | $0.25 | $-0.60 | $-0.70 | $-1.57 | $-2.29 |
| EBITDA | -$361.2K | -$14.2M | -$7.9M | -$30.8M | -$53.4M |
| Operating cash flow | $8.3M | $17.5M | $8.8M | -$22.9M | -$33.1M |
| Free cash flow | $6.4M | $16.0M | $8.6M | -$23.3M | -$33.3M |
| Diluted shares | 45.1M | 41.2M | 33.9M | 31.0M | 27.0M |
Balance sheet
| Period end | Dec 31 | Dec 31 | Dec 31 | Dec 31 | Dec 31 |
|---|---|---|---|---|---|
| Cash & equivalents | $36.8M | $32.7M | $33.1M | $4.0M | $41.3M |
| Short-term investments | $0.00 | $0.00 | $0.00 | $0.00 | — |
| Total debt | $0.00 | $18.3M | $18.3M | $2.8M | $63.4K |
| Total assets | $70.4M | $76.1M | $58.5M | $25.7M | $49.9M |
| Total liabilities | $47.3M | $83.7M | $52.9M | $33.0M | $24.1M |
| Shareholders' equity | $23.2M | -$7.6M | $5.6M | -$11.9M | $21.7M |
From SEC filings via Massive. Fiscal periods follow the company's own calendar; free cash flow is operating cash flow minus capital expenditure.
Sources: Massive / Polygon daily aggregates (split-adjusted) · SEC filings via Massive · FINRA settlements via Massive · Financial Modeling Prep. Figures are dated where shown; research is informational, not investment advice. Methodology